Related Experiment Video
Updated: Aug 30, 2025

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
Testosterone Replacement Therapy in Chronic Kidney Disease Patients
Ryszard Skiba1, Aleksandra Rymarz2, Anna Matyjek2
1Department of General, Functional and Oncological Urology, Military Institute of Medicine, 04-141 Warsaw, Poland.
Insights
Testosterone replacement therapy (TRT) effectively improved hypogonadism symptoms and erectile dysfunction in men with chronic kidney disease (CKD) and those on hemodialysis. The treatment showed no significant safety risks regarding overhydration or prostate-specific antigen (PSA) levels.
Area of Science:
- Nephrology
- Endocrinology
- Urology
Background:
- Chronic kidney disease (CKD) and hemodialysis (HD) are associated with hypogonadism.
- Hypogonadism affects a significant percentage of men with CKD (52%) and on HD (68.4%).
Purpose of the Study:
- To evaluate the efficacy and safety of testosterone replacement therapy (TRT) in men with CKD and hypogonadism.
- Assessed TRT in conservative (predialysis) and hemodialysis patient groups.
Main Methods:
- 38 HD patients, 46 predialysis (PreD) CKD patients, and 35 controls were studied.
- TRT administered via intramuscular testosterone enanthate injections every 3 weeks.
- Safety monitored via prostate-specific antigen (PSA) and overhydration assessments.
Main Results:
- Significant increase in total testosterone (TT) and free testosterone (fT) after 3 months of TRT.
- Gradual decrease in hypogonadism symptoms (ADAM questionnaire) and erectile dysfunction (IIEF-5) over 12 months.
- No significant changes in TT and fT after 3 months, and no significant safety concerns (PSA, overhydration).
Conclusions:
- TRT effectively corrects clinical hypogonadism signs in CKD and HD patients.
- The TRT regimen is safe, with no significant risk of overhydration or PSA elevation.
- TRT offers a viable treatment option for hypogonadism in kidney disease patients.
Abstract:
(Background) The aim of our study was to evaluate the efficacy and safety of testosterone replacement therapy (TRT) in men with chronic kidney disease and hypogonadism on conservative and hemodialysis treatment. (Methods) The studied population consisted of 38 men on hemodialysis (HD), 46 men with CKD stages II-IV (predialysis group, PreD) and 35 men without kidney disease who were similar in age to others (control group). Serum total testosterone level (TT) was measured, and free testosterone level (fT) was calculated. Hypogonadism criteria according to the EAU definition were fulfilled by 26 men on HD (68.4%) and by 24 men from the PreD group (52%). Testosterone replacement therapy (TRT) with testosterone enanthate in intramuscular injections every 3 weeks was applied in 15 men from HD and in 14 men from PreD. The safety of TRT was monitored by measuring PSA and overhydration. (Results) A significant rise of TT and fT was observed after 3 months of TRT, but no significant changes were observed after 6 and 12 months in the HD and PreD group. An intensity of clinical symptoms of hypogonadism measured by ADAM (androgen deficiency in the ageing male) questionnaire gradually decreased, and the intensity of erectile dysfunction measured by the IIEF-5 (international index of erectile functioning) questionnaire also decreased after 3, 6 and 12 months of TRT in the HD and PreD group. (Conclusions) The applied model of TRT is effective in the correction of clinical signs of hypogonadism without a significant risk of overhydration or PSA changes.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease I: Introduction
Kidney Transplant I: Introduction
Chronic Kidney Disease II: Clinical Manifestations
Acute Kidney Injury V: Interprofessional Care
Continuous Renal Replacement Therapy

